12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Serelaxin: Additional Phase III data

Additional data from the 6-month, double-blind, international Phase III RELAX-AHF trial in 1,161 patients showed that RLX030 plus standard of care (SOC) met the co-primary endpoint of improving dyspnea as measured by VAS scores through day 5 vs. placebo (p=0.0075), but missed the co-primary endpoint of improving patient-reported dyspnea on the Likert scale at 6, 12 and 24 hours (p=0.702). RLX030 also missed the secondary endpoints of increasing the number of days alive and out of the hospital up to day 60 vs. placebo (48.3 vs....

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >